ArticleCrohn's & colitis 3602026

Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease.

Ellen Axenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.